Compare
China Pharma Holdings, Inc. vs ProPhase Labs, Inc. vs Camp4 Therapeutics Corp vs TherapeuticsMD, Inc.
| Latest fiscal year | China Pharma Holdings, Inc. CPHI | ProPhase Labs, Inc. PRPH | Camp4 Therapeutics Corp CAMP | TherapeuticsMD, Inc. TXMD |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $4.14M | $4.34M | $3.50M | $3.02M |
| Revenue growth (YoY) | -8.5% | -35.8% | +436.5% | +71.6% |
| Gross margin | -3.2% | 31.9% | n/a | n/a |
| Operating margin | -78.2% | -415.4% | n/m | -145.3% |
| Net margin | -76.9% | -339.3% | n/m | -18.8% |
| Net income | -$3.19M | -$14.74M | -$80.40M | -$569.0K |
| EPS (Diluted) | -$0.74 | -$1.74 | -$2.65 | -$0.05 |
| Operating cash flow | $148.3K | -$8.34M | -$29.55M | $2.45M |
| Free cash flow | $88.9K | -$8.34M | -$29.83M | n/a |
| Cash & equivalents | $345.1K | $90.0K | $109.52M | n/a |
| Total assets | $31.00M | $59.87M | $117.81M | $37.66M |
| Total liabilities | $8.26M | $56.36M | $70.10M | $10.78M |
| Shareholders' equity | $22.74M | $3.51M | $47.70M | $26.88M |
| Return on year-end equity | -14.0% | -420.3% | -168.5% | -2.1% |
| Shares outstanding | 15.52M | 8.97M | 51.90M | 11.57M |
Revenue, most recent five fiscal years
| Fiscal year | China Pharma Holdings, Inc. | ProPhase Labs, Inc. | Camp4 Therapeutics Corp | TherapeuticsMD, Inc. |
|---|---|---|---|---|
| Latest | $4.14M Ended 2025-12-31 | $4.34M Ended 2025-12-31 | $3.50M Ended 2025-12-31 | $3.02M Ended 2025-12-31 |
| 1 year earlier | $4.53M Ended 2024-12-31 | $6.77M Ended 2024-12-31 | $652.0K Ended 2024-12-31 | $1.76M Ended 2024-12-31 |
| 2 years earlier | $7.01M Ended 2023-12-31 | $34.98M Ended 2023-12-31 | $350.0K Ended 2023-12-31 | $1.30M Ended 2023-12-31 |
| 3 years earlier | $8.10M Ended 2022-12-31 | $122.65M Ended 2022-12-31 | n/a | $69.96M Ended 2022-12-31 |
| 4 years earlier | $9.64M Ended 2021-12-31 | $79.04M Ended 2021-12-31 | n/a | $2.57M Ended 2021-12-31 |